Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Trial in Progress: A Multicenter, Open Label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy

Gail J. Roboz, Ahmed Aribi, Adrian Ochsenbein, Carsten Riether, Monic J. Stuart, Emily Mitchell, Komal Changela, Adam George, Michael Boyiadzis, Clayton Smith, Thomas Pabst

Blood (2024) 144 (Supplement 1): 1504.2.

https://doi.org/10.1182/blood-2024-202648

Published: 2024

Journal Articles

Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis

Ayalew Tefferi, MD, Kebede Begna, MD, Rebecca R. Laborde, PhD, Mrinal M Patnaik, MBBS, Terra L Lasho, MT, (ASCP), Darci Zblewski, Christy Finke, BS, Lauren Schimek, Betsy R. LaPlant, Curtis A. Hanson, MD, Monic J. Stuart, MD, MPH, Animesh Pardanani, MBBS, PhD

Blood (2013) 122 (21): 662.

https://doi.org/10.1182/blood.V122.21.662.662

Published: 2013

Journal Articles

Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results

Gabriela M. Baerlocher, MD, Elisabeth Oppliger Leibundgut, PharmD, Christina Ayran, Martha Blaney, PharmD, Bart Burington, Ph.D, Dianne Morfeld, Olatoyosi Odenike, MD, Oliver Ottman, MD, Anita Reddy, PhD, Alexander Roeth, MD, Gary Spitzer, MD, Monic J. Stuart, MD, MPH, Srdan Verstovsek, MD, PhD, David S. Snyder, MD

Blood (2012) 120 (21): 179.

https://doi.org/10.1182/blood.V120.21.179.179

Published: 2012

Journal Articles

The Telomerase Inhibitor, Imetelstat, Rapidly Reduces Myeloma Cancer Stem Cells (CSCs) in a Phase II Trial

Carol Ann Huff, M.D., Quiju Wang, MS, Ashraf Z. Badros, MD, Richard J. Jones, Anita Reddy, PhD, Kevin Nishimoto, PhD, Monic J. Stuart, MD, MPH, Stephen M Kelsey, MD, William Matsui, MD

Blood (2012) 120 (21): 4898.

https://doi.org/10.1182/blood.V120.21.4898.4898

Published: 2012

Journal Articles

Imetelstat, A Potent Telomerase Inhibitor, Inhibits the Spontaneous Growth of CFU-Meg In Vitro From Essential Thrombocythemia Patients but Not From Healthy Individuals,

Claudio Brunold, Thomas R Braschler, Ning Go, MD, Joi Ninomoto, PharmD, Hooman Kashani, MS DABT, Monic J. Stuart, MD, MPH, Elisabeth Oppliger Leibundgut, PharmD, Gabriela M. Baerlocher, MD

Blood (2011) 118 (21): 3843.

https://doi.org/10.1182/blood.V118.21.3843.3843

Published: 2011

Journal Articles

Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8 + T-cell dose

Thai M. Cao, Judith A. Shizuru, Ruby M. Wong, Kevin Sheehan, Ginna G. Laport, Keith E. Stockerl-Goldstein, Laura J. Johnston, Monic J. Stuart, F. Carl Grumet, Robert S. Negrin, Robert Lowsky

Blood (2005) 105 (6): 2300–2306.

https://doi.org/10.1182/blood-2004-04-1473

Published: 2005

Includes: Supplemental data

Journal Articles

Effective Containment of Human Respiratory Syncytial Virus Infections in a Bone Marrow Transplantation Program Resulting from the Combined Implementation of Molecular Epidemiology, Infection Control, and Early Treatment Strategies.

Steven S. Cha, MD, Monic J. Stuart, MD, Susan Poutanen, MD, Sasha Madison, MD, Ellen Jo Baron, MD, Dean Erdman, MD, Janice M. Brown, MD.

Blood (2004) 104 (11): 2225.

https://doi.org/10.1182/blood.V104.11.2225.2225

Published: 2004

Journal Articles

Engraftment and Survival Following Non-Myeloablative Allogeneic Peripheral Blood Hematopoietic Cell Transplantation for Malignant Diseases Is Affected by CD8 + T-Cell Dose.

Thai M. Cao, MD, Judith A. Shizuru, PhD, MD, Ruby M. Wong, PhD, Kevin Sheehan, PhD, Ginna G. Laport, MD, Keith E. Stockerl-Goldstein, MD, Laura J. Johnston, MD, Monic J. Stuart, MD, Janic M.Y. Brown, MD, F. C. Grumet, MD, Robert S. Negrin, MD, Robert Lowsky, MD

Blood (2004) 104 (11): 183.

https://doi.org/10.1182/blood.V104.11.183.183

Published: 2004

Journal Articles

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

Steven M. Horwitz, Robert S. Negrin, Karl G. Blume, Sheila Breslin, Monic J. Stuart, Keith E. Stockerl-Goldstein, Laura J. Johnston, Ruby M. Wong, Judith A. Shizuru, Sandra J. Horning

Blood (2004) 103 (3): 777–783.

https://doi.org/10.1182/blood-2003-04-1257

Published: 2004

Journal Articles

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

Wolfgang A. Bethge, Ute Hegenbart, Monic J. Stuart, Barry E. Storer, Michael B. Maris, Mary E. D. Flowers, David G. Maloney, Thomas Chauncey, Benedetto Bruno, Ed Agura, Stephen J. Forman, Karl G. Blume, Dietger Niederwieser, Rainer Storb, Brenda M. Sandmaier

Blood (2004) 103 (3): 790–795.

https://doi.org/10.1182/blood-2003-07-2344

Published: 2004

NARROW

Trial in Progress: A Multicenter, Open Label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy

Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis

Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results

The Telomerase Inhibitor, Imetelstat, Rapidly Reduces Myeloma Cancer Stem Cells (CSCs) in a Phase II Trial

Imetelstat, A Potent Telomerase Inhibitor, Inhibits the Spontaneous Growth of CFU-Meg In Vitro From Essential Thrombocythemia Patients but Not From Healthy Individuals,

Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8 + T-cell dose

Effective Containment of Human Respiratory Syncytial Virus Infections in a Bone Marrow Transplantation Program Resulting from the Combined Implementation of Molecular Epidemiology, Infection Control, and Early Treatment Strategies.

Engraftment and Survival Following Non-Myeloablative Allogeneic Peripheral Blood Hematopoietic Cell Transplantation for Malignant Diseases Is Affected by CD8 + T-Cell Dose.

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only